NCT05944952View on ClinicalTrials.gov

Low-dose Versus a High-dose Sublingual Buprenorphine Induction

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

October 30, 2025

Conditions

Opioid Use Disorder

Interventions

DRUG

buprenorphine/naloxone

Participants will be dosed with buprenorphine/ naloxone strips

Trial Locations (1)

21222

MATClinics, Dundalk

Sponsors

Lead Sponsor

Friends Research Institute, Inc.

Collaborators (1)

All Listed Sponsors

collaborator

MATClinics

UNKNOWN

lead

Friends Research Institute, Inc.

OTHER